Sera Prognostics, Inc. (SERA) Key Metrics

NASDAQ: SERAValuation, returns, debt and efficiency ratios over 7 years.

SERA valuation today

Trailing 12 months · as of October 18, 2026
Market cap
$81.3M
Enterprise value
$38.2M
P/E (TTM)
—
Forward P/E
—
PEG ratio
—
Price / sales
—
Price / book
1.4
10-yr median 1.9
EV / EBITDA
—
Dividend yield
—
Beta
1.06

SERA key metrics, 2019–2025

Fiscal year ended December 31, 2025 · U.S. dollars

SERA valuation Price multiples at each fiscal year-end price.

Price / book−67.0%
1.9
2025 · hover or tap a bar for each year
2021: 1.52022: 0.4 (−74.2%)2023: 2.7 (+574.9%)2024: 5.6 (+112.3%)2025: 1.9 (−67.0%)
20192025
Free cash flow yield−13.1 pts
−18.7%
2025 · hover or tap a bar for each year
2021: −15.6%2022: −90.8% (−75.2 pts)2023: −14.6% (+76.2 pts)2024: −5.7% (+9.0 pts)2025: −18.7% (−13.1 pts)
20192025

SERA valuation history

Fiscal year-endToday7-year median

SERA returns on capital

ROEROICROA

Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.

SERA debt vs cash

Total debtCash & short-term investments

Debt includes short- and long-term borrowings and, where reported, lease liabilities.

SERA price vs earnings per share

Share price at year-endEPS (right axis)

SERA key metrics

2019–2025
Sera Prognostics, Inc. key metrics by fiscal year
2025202420232022202120202019
Valuation
Market capitalization$140.6M$269.9M$186.6M$39.0M$211.4M——
Enterprise value$103.7M$224.5M$139.4M−$40.9M$106.4M——
Price / sales——609.7145.5———
Price / book1.95.62.70.41.5——
EV / sales——455.4-152.6———
Earnings yield−22.7%−12.2%−19.4%−113.3%−16.6%——
Free cash flow yield−18.7%−5.7%−14.6%−90.8%−15.6%——
Shareholder yield (dividends + buybacks)———0.0%0.0%——
Share price at fiscal year-end$2.95$8.14$5.98$1.26$6.87——
Per share
Revenue per share$0.00$0.00$0.01$0.01$0.00$0.00$0.00
Earnings per share−$0.67−$0.99−$1.16−$1.43−$1.14−$1.10−$0.91
Operating cash flow per share−$0.54−$0.43−$0.87−$1.12−$1.03−$0.93−$1.07
Free cash flow per share−$0.55−$0.46−$0.88−$1.14−$1.07−$0.94−$1.07
Cash per share$0.82$1.39$1.57$2.67$3.42$0.75$1.18
Book value per share$1.58$1.44$2.25$3.20$4.50$0.16$0.61
Tangible book value per share$1.56$1.41$2.25$3.20$4.50$0.16$0.61
Capex per share$0.02$0.03$0.00$0.03$0.04$0.01$0.01
Debt per share$0.05$0.03$0.06$0.09$0.00$0.47$0.51
Shares outstanding47.7M33.2M31.2M30.9M30.8M18.1M18.1M
Change in shares outstanding+43.7%+6.3%+0.8%+0.6%+70.0%0.0%—
Returns & profitability
Return on equity (ROE)−51.8%−55.8%−42.9%−37.2%−49.5%−285.7%−150.8%
Return on invested capital (ROIC)−140.8%−228.4%−149.8%−137.0%−177.2%——
Return on assets (ROA)−36.6%−39.2%−34.2%−33.6%−43.3%−104.3%−71.0%
Return on tangible assets−31.6%−46.0%−38.0%−38.0%−23.8%−134.1%−71.0%
Financial health
Total debt$2.3M$840,000$1.9M$2.8M$128,000$8.6M$9.3M
Cash & short-term investments$39.2M$46.2M$49.1M$82.7M$105.1M$13.5M$21.4M
Net debt−$36.9M−$45.4M−$47.2M−$79.9M−$105.0M−$5.0M−$12.1M
Debt / equity0.030.020.030.030.002.920.85
Debt / assets0.020.010.020.020.000.580.40
Current ratio1.691.922.515.8013.111.223.65
Quick ratio1.691.922.515.8013.111.223.65
Interest coverage——-724.0-748.4-47.4-9.8-8.4
Working capital$16.6M$22.8M$36.9M$74.6M$101.8M$2.5M$15.6M
Invested capital$38.5M$2.4M$22.9M$19.1M$33.6M−$2.0M−$1.1M
Tangible asset value$74.5M$46.8M$70.2M$98.9M$138.6M$2.9M$11.0M
Net current asset value$14.2M$22.8M$36.1M$72.7M$101.8M$1.9M$9.2M
Graham net-net per share$0.27$0.65$1.04$2.26$3.22$0.09$0.50
Capital allocation
Share buybacks (net)———$0$0——
Capex / revenue896.3%1,429.9%41.8%295.1%1,590.2%596.0%302.8%
Capex / depreciation0.771.320.141.051.980.170.12
Stock-based compensation / revenue6,308.6%9,107.8%1,723.2%1,886.2%3,817.1%2,904.0%1,216.7%
R&D / revenue16,260.5%19,129.9%4,975.5%5,314.9%13,437.8%31,128.0%25,980.6%
SG&A / revenue28,703.7%28,441.6%8,069.3%11,747.4%29,781.7%40,812.0%20,113.9%
Efficiency
Days sales outstanding103.627,266.010,486.66,303.16,999.521.910.1
Days of inventory on hand———0.0——0.0
Days payables outstanding3,150.46,710.22,254.32,595.78,079.319,726.615,167.8
Cash conversion cycle (days)-3,046.720,555.88,232.33,707.4-1,079.8-19,704.7-15,157.6
Receivables turnover3.520.010.030.060.0516.6736.00
Payables turnover0.120.050.160.140.050.020.02
Inventory turnover———193,000.00——18,000.00
Asset turnover0.000.000.000.000.000.000.00
Average receivables$23,000$5.8M$8.8M$4.6M$1.6M$1,500$1,000
Average payables$1.4M$1.5M$1.3M$1.4M$819,000$594,500$748,000
Average inventory———$1——$1
Intangibles / total assets0.9%1.4%0.0%0.0%0.0%0.0%0.0%

Computed from SERA's annual financial statements (latest annual report filed March 18, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.

SERA valuation and financial ratios

Sera Prognostics earned a return on equity of −51.8% and a return on invested capital of −140.8% in fiscal 2025. It ended the year with $2.3 million of debt and $39.2 million in cash and short-term investments, a net cash position of $36.9 million. The share count rose 163.2% from 18.1M to 47.7M over 6 years.

See the SERA income statement, the SERA chart for price history, or the SERA stock overview for the latest quote and news.

SERA key metrics FAQ

What is Sera Prognostics's return on equity?

Sera Prognostics's return on equity (ROE) was −51.8% in fiscal 2025: net income of -$31.9 million on average shareholders' equity of $61.6 million.

What is Sera Prognostics's ROIC?

Sera Prognostics's return on invested capital was −140.8% in fiscal 2025, using after-tax operating income divided by average debt plus equity minus cash.

How much debt does Sera Prognostics have?

Sera Prognostics had total debt of $2.3 million at the end of fiscal 2025, a debt-to-equity ratio of 0.03 and more cash than debt.

What is Sera Prognostics's free cash flow yield?

Sera Prognostics generated -$26.3 million of free cash flow in fiscal 2025, a free cash flow yield of −18.7% on its market value at year-end ($140.6 million).

What is Sera Prognostics's current ratio?

Sera Prognostics's current ratio was 1.69 at the end of fiscal 2025: current assets were 1.69 times current liabilities.

Medical Devices key metrics